Concepedia

Ying Wang

YW

Statistics

Publications

3

Citations

853

H-Index

3

Active since

2021

Affiliations

AstraZeneca (United States)(Current)

Memorial Sloan Kettering Cancer Center

AstraZeneca (Japan)

Ying Wang is an author at AstraZeneca (United States) specializing in oncology, esophageal cancer, and immunotherapy.

ORCID

Publications per year

2021–2025

3

Publications

3

Effect of Camrelizumab vs Placebo Added to Chemotherapy on Survival and Progression-Free Survival in Patients With Advanced or Metastatic Esophageal Squamous Cell Carcinoma

Jin Lü, Yuxian Bai, Teng Mao et al. · JAMA · 2021 · 801 citations · Full text

, , +17

Circulating tumor DNA (ctDNA) in patients with muscle-invasive bladder cancer (MIBC) who received perioperative durvalumab (D) in NIAGARA.

Thomas Powles, Michiel Simon Van Der Heijden, Ying Wang et al. · Journal of Clinical Oncology · 2025 · 35 citations

, , +16

A Phase Ib/II Randomized Clinical Trial of Oleclumab with or without Durvalumab plus Chemotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma

Andrew L. Coveler, Matthew J. Reilley, Mark M. Zalupski et al. · Clinical Cancer Research · 2024 · 17 citations · Full text

, , +17

1–3 of 3